Trial | AXIS | AXIS | METEOR | AXIS | METEOR |
---|---|---|---|---|---|
Arm | Axitinib, before matching (N = 194) | Axitinib, after matching vs. cabozantinib (ESS = 104/114) | Cabozantinib (N = 135) | Axitinib, after matching vs. everolimus (ESS = 61/95) | Everolimus (N = 132) |
Sex, % | |||||
 Male | 74 | 79 | 79 | 72 | 72 |
 Female | 26 | 21 | 21 | 28 | 28 |
Median age, years | 62 | 62 | 62 | 62 | 62 |
Geographic regions, % | |||||
 Europe | 51 | 53 | 53 | 50 | 50 |
 North America | 29 | 33 | 33 | 33 | 33 |
 Asia | 15 | 13 | 13 | 17 | 17 |
 Other | 5 | < 1 | < 1 | 1 | 1 |
ECOG PS or KPS, % | |||||
 0 (KPS 90–100) | 52 | 70 | 70 | 66 | 66 |
 1 (KPS 70–80) | 48 | 30 | 30 | 34 | 34 |
MSKCC in the base-case analysis, % | |||||
 Favourable | 20 | 41 | 41 | 45 | 45 |
 Intermediate | 42 | 47 | 47 | 44 | 44 |
 Poor | 34 | 13 | 13 | 11 | 11 |
 NR | 4 | 0 | 0 | 0 | 0 |
MSKCC in the sensitivity analysis, % | |||||
 Favourable | 33 | 41 | 41 | 45 | 45 |
 Intermediate | 58 | 47 | 47 | 44 | 44 |
 Poor | 5 | 13 | 13 | 11 | 11 |
 NR | 4 | 0 | 0 | 0 | 0 |
Histology, % | |||||
 Clear cell or clear cell component | 98 | 100 | 100 | 100 | 100 |
Metastatic site, % | |||||
 Lung | 73 | 59 | 59 | 67 | 67 |
 Bone | 30 | 20 | 20 | 42 | 42 |
 Liver | 33 | 32 | 32 | 17 | 17 |
Prior nephrectomy, % | 88 | 86 | 86 | 85 | 85 |
Prior radiotherapy, % | 23 | 29 | 29 | 31 | 31 |